沃森生物(300142.SZ):雲南疫苗實驗室有限公司已辦理完成工商登記手續並取得營業執照
格隆匯4月5日丨沃森生物(300142.SZ)公佈,此前披露,公司於2023年1月收到《雲南省科技領導小組辦公室關於批准籌建雲南疫苗實驗室(籌)的通知》,經雲南省科技領導小組同意,批准公司牽頭籌建“雲南疫苗實驗室(籌)”,籌建期由公司進行前期投入,建設期內雲南省科技廳通過後補助,支持實驗室科技項目的實施。
獲得上述批准後,公司積極推進雲南疫苗實驗室的籌建工作。經公司總裁辦公會審議通過,公司以自有資金3000萬元,在雲南省昆明市高新區沃森生物科技創新中心出資設立全資子公司雲南疫苗實驗室有限公司,作為雲南疫苗實驗室的運營主體。公司將結合戰略發展需求,利用公司在臨牀研究、技術轉移、產業化建設和運營管理能力等方面的綜合優勢,以國家戰略疫苗需求為導向,以雲南產業需求為核心,在雲南省人民政府統籌指導下,加快推進實驗室的建設發展。
近日,雲南疫苗實驗室有限公司已辦理完成工商登記手續並取得了工商行政管理部門頒發的《營業執照》。
此次出資成立該全資子公司是推進雲南疫苗實驗室建設的重要環節,有利於推動公司在現有基礎上繼續優化深耕各大技術平台,推動系列疫苗開發,佈局全球重磅產品,打造創新型疫苗研發體系;同時,有利於加快打通產學研用產業鏈,聚合疫苗創新資源,實現技術資源共享和優勢互補,促進公司的健康長遠發展,符合公司的整體發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.